Mersana Therapeutics Announces Strategic Priorities and Goals for 2019 and Beyond
Company to Focus its Resources on Advancing XMT-1536, its First-in-Class ADC Candidate Targeting NaPi2b, Showing Encouraging Early Signs of Efficacy Dose Selection and Initiation of XMT-1536 Expansion Cohorts on Track for First Half 2019 XMT-1522 …